Acute Myocarditis Related to COVID-19 : Comparison to SARS and MERS
© Springer Nature Switzerland AG 2020..
Myocardial involvement has been described during previous SARS and MERS outbreaks. Infection by SARS-CoV-2 (COVID-19) can range from asymptomatic to life-threatening multi-system disease. Heart involvement most commonly occurs during severe COVID-19 infection. Myocardial injury, based on elevated levels of myocardial enzymes, has been noted in up to 30% of patients with COVID-19 infection and could be a marker for worse prognosis. A few cases of possible myocarditis due to SARS-CoV-2 have been described, providing variable degree of evidence of direct myocardial involvement. We reviewed in detail those cases in comparison to relevant literature on SARS and MERS and attempted to draw initial conclusions in regard to clinical presentation, treatment and prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
SN comprehensive clinical medicine - 2(2020), 12 vom: 27., Seite 2684-2690 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chasouraki, Angeliki M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 18.02.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s42399-020-00563-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318026767 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318026767 | ||
| 003 | DE-627 | ||
| 005 | 20231225164510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s42399-020-00563-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1060.xml |
| 035 | |a (DE-627)NLM318026767 | ||
| 035 | |a (NLM)33235977 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chasouraki, Angeliki M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acute Myocarditis Related to COVID-19 |b Comparison to SARS and MERS |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © Springer Nature Switzerland AG 2020. | ||
| 520 | |a Myocardial involvement has been described during previous SARS and MERS outbreaks. Infection by SARS-CoV-2 (COVID-19) can range from asymptomatic to life-threatening multi-system disease. Heart involvement most commonly occurs during severe COVID-19 infection. Myocardial injury, based on elevated levels of myocardial enzymes, has been noted in up to 30% of patients with COVID-19 infection and could be a marker for worse prognosis. A few cases of possible myocarditis due to SARS-CoV-2 have been described, providing variable degree of evidence of direct myocardial involvement. We reviewed in detail those cases in comparison to relevant literature on SARS and MERS and attempted to draw initial conclusions in regard to clinical presentation, treatment and prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Corticosteroids | |
| 650 | 4 | |a Myocardial injury | |
| 650 | 4 | |a Myocarditis | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a Troponin | |
| 700 | 1 | |a Violetis, Odyssefs A |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelrasoul, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Tsagalou, Eleftheria P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t SN comprehensive clinical medicine |d 2019 |g 2(2020), 12 vom: 27., Seite 2684-2690 |w (DE-627)NLM300071965 |x 2523-8973 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2020 |g number:12 |g day:27 |g pages:2684-2690 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s42399-020-00563-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2020 |e 12 |b 27 |h 2684-2690 | ||